Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 8/17/2025

Treatment of Rheumatic Diseases

Initial Treatment

  • The European League Against Rheumatism recommends starting high-dose glucocorticoids immediately (40-60 mg/day prednisone equivalent) without waiting for confirmatory tests, and considering intravenous methylprednisolone (0.25-1g/day for up to 3 days) for patients with visual symptoms 1

Disease Management

  • Once disease is controlled, taper dose to 15-20 mg/day within 2-3 months and to ≤5 mg/day after 1 year, as recommended by the European League Against Rheumatism and the American College of Rheumatology 1
  • Carotid artery plaque formation is primarily managed through addressing modifiable risk factors that contribute to atherosclerosis, with intensive medical therapy being the recommended management approach for patients with 10-30% carotid artery plaque formation, focusing on aggressive risk factor modification and pharmacological interventions to prevent stroke and disease progression, including antihypertensive therapy, high-dose statin therapy, smoking cessation, and diabetes management 2
  • Antiplatelet therapy with low-dose aspirin (75-100mg daily) or clopidogrel (if aspirin intolerant) is recommended for all patients with carotid artery disease, as suggested by the European Society of Cardiology, the American College of Cardiology, and the American Heart Association 3, 4, 2, 5
  • Aggressive LDL cholesterol lowering can stabilize and potentially regress atherosclerotic plaques, with a target LDL-C <70 mg/dL for optimal plaque stabilization, as demonstrated by the SPARCL trial and reported in Arteriosclerosis, Thrombosis, and Vascular Biology, with a moderate to high strength of evidence based on clinical studies 2, 6

Risk Factor Management

  • Regular moderate physical exercise, weight management, and a healthy diet are important for overall vascular health, as recommended by the American Heart Association 2, 7, 5
  • Blood pressure control, with a target <140/90 mmHg, individualized based on comorbidities, is essential for reducing the risk of stroke 2
  • Smoking cessation is crucial, as smoking increases relative risk of ischemic stroke by 25-50%, and stroke risk decreases substantially within 5 years after quitting, with active counseling and pharmacotherapy recommended for all smokers 2
  • Diabetes management, with a target HbA1c <7% for most patients, is important for overall vascular health, although intensive glycemic control has not shown clear stroke reduction benefits 2

Monitoring and Surveillance

  • Regular carotid duplex ultrasound surveillance is recommended, with monitoring every 12 months for stable plaque and more frequent monitoring if rapid progression is noted, as well as assessment for development of neurological symptoms and monitoring and adjustment of risk factor management as needed 2
  • Brain imaging (MRI preferred over CT) should be performed to evaluate for silent infarcts, as recommended by the American Academy of Ophthalmology and the International Journal of Stroke guidelines 8, 9
  • Regular ophthalmologic follow-up, periodic carotid ultrasound (annually if significant stenosis present), and ongoing cardiovascular risk factor management are recommended for long-term monitoring of patients with Hollenhorst plaques, as stated by the American Heart Association 10

Interventional Management

  • Carotid endarterectomy or stenting is recommended for patients with stenosis >70% by noninvasive imaging or >50% by catheter angiography, with the American College of Cardiology stating that the benefit of carotid endarterectomy diminishes with time after the initial event 5, 10, 2
  • Revascularization is generally not indicated unless the patient becomes symptomatic or shows significant progression, according to the Stroke journal 11

Stroke Risk Assessment

  • The presence of multiple vascular risk factors increases the risk of stroke after amaurosis fugax, with the American Heart Association recommending aggressive risk factor management, including blood pressure control, smoking cessation, diabetes management, and weight management and exercise 5
  • The risk of stroke after amaurosis fugax varies based on the number of vascular risk factors, with a 3-year stroke risk of:
Risk Factors 3-Year Stroke Risk
0-1 1.8%
2 12.3%
3-4 24.2%

Giant Cell Arteritis (GCA) Management

  • Evaluate for signs of GCA, as this requires immediate treatment, and initiate high-dose glucocorticoids (40-60 mg/day prednisone equivalent) immediately if GCA is suspected, according to the European League Against Rheumatism and the American College of Rheumatology 1
  • ESR/CRP should be evaluated to assess for possible GCA, as recommended by the American College of Rheumatology 1
  • Visual symptoms in suspected GCA require immediate treatment as delaying therapy is the strongest risk factor for permanent blindness 1

Additional Therapies

  • Hyperbaric oxygen therapy (100% oxygen over 9 hours) has demonstrated efficacy over observation alone in several small randomized trials, as reported by the Undersea and Hyperbaric Medical Society 7
  • For patients who develop iris or retinal neovascularization, panretinal photocoagulation (PRP) with or without anti-VEGF therapy should be considered, according to the American Academy of Ophthalmology 7

REFERENCES